Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
October 18, 2023 08:00 ET
|
Caribou Biosciences, Inc.
-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the...
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
September 27, 2023 08:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Caribou Biosciences to Participate in Upcoming Investor Conferences
August 29, 2023 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 16:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1...
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
July 13, 2023 23:15 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of...
Caribou Biosciences Announces Proposed Public Offering of Common Stock
July 13, 2023 16:03 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has...
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
July 13, 2023 16:01 ET
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR)...
Caribou Biosciences to Participate in Upcoming Investor Conferences
May 31, 2023 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023 16:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients...
Caribou Biosciences to Participate in Upcoming Investor Conferences
May 01, 2023 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...